Altimmune's Intranasal COVID-19 Vaccine Candidate Shows Sterilizing Immunity After Single Dose

  • Altimmune Inc ALT has announced positive results from a preclinical study evaluating its intranasal COVID-19 vaccine candidate, AdCOVID, in a SARS-CoV-2 challenge model of infection.
  • The results showed that a single dose of AdCOVID provided sterilizing immunity in the lungs of vaccinated mice, in contrast to the development of dense pulmonary infection and disease in the lungs of non-vaccinated mice following infection with SARS-CoV-2.
  • No detectable levels of infectious virus were observed in the lungs of vaccinated mice, representing a greater than one million-fold reduction compared to the non-vaccinated controls.
  • The ongoing Phase 1 trial evaluates the safety and immunogenicity of AdCOVID following a single dose or two intranasal doses administered one month apart.
  • Topline data is expected next month.
  • Price Action: ALT shares are up 4.37% at $13.85 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!